What Early COPERNICUS Safety Data Mean for Practice

Luis E. Raez, MD, of Miami Cancer Institute, summarizes the early COPERNICUS conclusions: enhanced prophylaxis with subcutaneous amivantamab plus lazertinib led to low rates of severe rash, thrombosis, and infusion reactions, though shorter follow-up limits inference. Wade T. Iams, MD, of Tennessee Oncology, places the data in the context of the overall survival benefit seen in MARIPOSA, achieved despite a 34% discontinuation rate, and suggests safer administration could build on that benefit. Dr Raez tells patients who ask whether subcutaneous dosing is as effective as intravenous dosing that PALOMA showed equivalent pharmacokinetics with no loss of survival. Dr Iams says the data most clearly support older patients with more comorbidities who might otherwise receive monotherapy. Dr Raez would tell community colleagues that subcutaneous dosing is now the standard for epidermal growth factor receptor–mutated non–small cell lung cancer and that the MARIPOSA toxicity profile no longer reflects practice.